Luigi Segagni Lusignani
Overview
Explore the profile of Luigi Segagni Lusignani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zatorska B, Moser D, Diab-Elschahawi M, Ebner J, Lusignani L, Presterl E
J Mycol Med
. 2021 Aug;
31(4):101178.
PMID: 34388399
Background: As infection control faces new challenges from emerging, multidrug resistant strains of the yeast Candida auris, this study was conducted in order to examine the efficacy of hospital surface...
2.
Lusignani L, Presterl E, Zatorska B, Van den Nest M, Diab-Elschahawi M
Antimicrob Resist Infect Control
. 2020 Jan;
9(1):18.
PMID: 31988746
Background: Carbapenemase-producing enterobacteriaceae (CPE) are a major threat for severely ill patients. However, only limited data on the epidemiology and on evidence-based infection prevention and control measures are available. The...
3.
Zatorska B, Arciola C, Haffner N, Lusignani L, Presterl E, Diab-Elschahawi M
Biomed Res Int
. 2018 Nov;
2018:1067413.
PMID: 30426000
In a retrospective study the association of the production of extracellular DNA (eDNA) in biofilms of clinical staphylococcal isolates from 60 patients with prosthetic joint infection (PJI) and the clinical...
4.
Lusignani L, Starzengruber P, Dosch V, Assadian O, Presterl E, Diab-Elschahawi M
Wien Klin Wochenschr
. 2017 Aug;
129(21-22):816-822.
PMID: 28776101
Background: Over the last 10 years, multidrug resistant Acinetobacter baumannii has been spreading worldwide as emerging microorganisms that negatively impact on the outcome of in-hospital patients. Methods: Between 2007 and...
5.
Zatorska B, Groger M, Moser D, Diab-Elschahawi M, Lusignani L, Presterl E
Clin Orthop Relat Res
. 2017 Feb;
475(8):2105-2113.
PMID: 28194715
Background: Prosthetic implant infections caused by Staphylococcus aureus and epidermidis are major challenges for early diagnosis and treatment owing to biofilm formation on the implant surface. Extracellular DNA (eDNA) is...
6.
Lusignani L, Blacky A, Starzengruber P, Diab-Elschahawi M, Wrba T, Presterl E
Wien Klin Wochenschr
. 2016 Jan;
128(3-4):89-94.
PMID: 26817781
Background: The first point prevalence survey performed in Austria had the aim to assess the magnitude of healthcare-associated infections and antimicrobials use in the country. Methods: A multicentre study was...
7.
Diab-Elschahawi M, Lusignani L, Starzengruber P, Mitteregger D, Wagner A, Assadian O, et al.
Antimicrob Resist Infect Control
. 2014 Dec;
3(1):38.
PMID: 25530847
Background: Current recommendations indicate that patients who are coughing and have multidrug resistant microorganisms (MDROs) in their sputum are considered to be shedders and should be cared for in single...
8.
Starzengruber P, Lusignani L, Wrba T, Mitteregger D, Indra A, Graninger W, et al.
Wien Klin Wochenschr
. 2014 Jun;
126(13-14):427-30.
PMID: 24903143
Background: Clostridium difficile infection (CDI) is the major cause of hospital-acquired bacterial diarrhoea. The incidence of CDI has been increasing in Canada, the US and Europe and severe cases are...
9.
Lusignani L, Quaglio G, Atzori A, Nsuka J, Grainger R, Palma M, et al.
BMC Infect Dis
. 2013 Apr;
13:168.
PMID: 23566166
Background: Tuberculosis (TB) is still a great challenge to public health in sub-Saharan Africa. Most transmissions occur between the onset of coughing and initiation of treatment. Delay in diagnosis is...
10.
Emanuele E, Lusignani L, Peros E, Montagna G, DAngelo A, Montagna L, et al.
Am J Nephrol
. 2004 Mar;
24(2):221-9.
PMID: 15017119
Background: Hemodialysis patients show a considerably higher risk of atherothrombotic disease than the general population. We investigated both lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to occurrence...